Erratum: Microtubule-targeting drugs induce Bcl-2 phosphorylation and association with Pin1 (Neoplasia (2001) 3 (550-559)

Neoplasia

Volumn 3, Issue 6, 2001, Pages 550-559

  Pathan, Nuzhat ^a   Aime Sempe, Christine ^a   Kitada, Shinichi ^a   Basu, Aruna ^b   Haldar, Subrata ^b   Reed, John C ^a  

^a BURNHAM INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Bcl 2; Cdc2; Mitosis; Phosphorylation; Pin1

Indexed keywords

ERRATUM; ERROR; PRIORITY JOURNAL; APOPTOSIS; ARTICLE; CELL LINE; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; GENETIC TRANSFECTION; HUMAN; KIDNEY; LEUKEMIA CELL LINE; METABOLISM; METAPHASE; MICROTUBULE; MITOSIS; PHOSPHORYLATION; PROTEIN ANALYSIS; PROTEIN PROCESSING; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION;

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTINEOPLASTIC AGENT; BISINDOLYLMALEIMIDE I; CYCLIN DEPENDENT KINASE 1; ENZYME INHIBITOR; FLAVONOID; FLAVOPIRIDOL; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE; NIMA INTERACTING PEPTIDYLPROLYL ISOMERASE; NIMA-INTERACTING PEPTIDYLPROLYL ISOMERASE; NOCODAZOLE; PEPTIDYLPROLYL ISOMERASE; PIPERIDINE DERIVATIVE; PROLINE; PROTEIN BCL 2; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CDC2 PROTEIN KINASE; CELL LINE; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; IMIDAZOLES; INDOLES; JURKAT CELLS; KIDNEY; MALEIMIDES; METAPHASE; MICROTUBULES; MITOSIS; MUTAGENESIS, SITE-DIRECTED; NOCODAZOLE; PEPTIDYLPROLYL ISOMERASE; PHOSPHORYLATION; PIPERIDINES; PROLINE; PROTEIN INTERACTION MAPPING; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 0035524625     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900213     Document Type: Erratum

References (57)

1. Bcl-2 family proteins
2. Bcl-2 family proteins: Regulators of apoptosis and chemoresistance in hematologic malignancies
3. Role of membrane anchor domain of Bcl-2 in suppression of apoptosis caused by E1B-defective adenovirus
4. Structure-function analysis of the bcl2 oncoprotein. Addition of a heterologous transmembrane domain to a portions of the bcl2 beta protein restore function as a regulator of cell survival
5. Investigation of the subcellular distribution of the bcl-2 oncoprotein: Residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes
6. X-ray and NMR structure of human Bcl-XL, an inhibitor of programmed cell death
7. L and Bcl-2
8. Deletion of a nonconserved region of Bcl-2 confers a novel gain of function: Suppression of apoptosis with concomitant cell proliferation
9. Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis
10. Loop domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis
11. Bcl-2 is phosphorylated and inactivated by an ask1/jun n-terminal protein kinase pathway normally activated at g(2)/m
12. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis
13. Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells
14. Microtubule-damaging drugs triggered bcl2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of bcl2 protein
15. Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1
16. A functional role for mitochondrial protein kinase Cα in Bcl-2 phosphorylation and suppression of apoptosis
17. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of Bcl-2 α in association with suppression of apoptosis
18. Inactivation of Bcl-2 by phosphorylation
19. Taxol induces Bcl-2 phosphorylation and death of prostate cancer cells
20. Bcl2 is the guardian of microtubule integrity
21. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 transduction pathway
22. Raf-1/bcl-2 phosphorylation: A step from microtubule damage to cell death
23. Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis
24. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and taxol-induced growth arrest
25. 3-(Iodoacetamido)-benzoylurea: A novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells
26. 2-Methoxyestradiol-induced phosphorylation of Bcl-2: Uncoupling from JNK/SAPK activation
27. Involvement of microtubules in the regulation of Bcl-2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase
28. Phosphorylation of Bcl-2 protein by CDC2 kinase during G2/M phases and its role in cell cycle regulation
29. Regulation of Bcl2 phosphorylation by stress response kinase pathway
30. Sequence-specific and phosphorylation-dependent proline isomerizaion: A potential mitotic regulatory mechanism
31. Requirement of the prolyl isomerase pin1 for the replication checkpoint
32. A strategy for generating monoclonal antibodies against recombinant baculovirus-produced proteins: Application to the Bcl-2 oncoprotein
33. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death
34. Reduced expression of pro-apoptotic gene Bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma
35. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line
36. Bcl-2 inhibits T-cell-mediated cytolysis of leukemia cell line
37. Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase
38. Bax inhibitor-1, a mammalian apoptosis suppressor identified by functional screening in yeast
39. Pre-B-cell leukemia with a t(14;18) translocation is preceded by follicular lymphoma
40. Calcineurin promotes apoptosis by dephosphorylating BAD
41. Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax
42. Bcl-2 targets the protein kinase Raf-1 to mitochondria
43. R-ras promotes apoptosis caused by growth factor deprivation via a Bcl-2 suppressible mechanism
44. How the cyclin became a cyclin: Regulated proteolysis in the cell cycle
45. Prolyl isomerases and nuclear function
46. Bcl-2-family proteins - The role of the BH3 domain in apoptosis
47. Channel formation by antiapoptotic protein Bcl-2
48. Bcl-2 phosphorylation required for anti-apoptosis function
49. Signaling and circuitry of multiple MAPK pathways revrealed by a matrix of global gene expression profiles
50. Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells
51. The apoptotic v-cyclin-CDK6 complex phosphorylates and inactivates Bcl-2
52. High levels of p26Bcl-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells
53. Mechanisms of nuclear protein import
54. Granzyme B induces apoptosis and cyclin a-associated cyclin-dependent kinase activity in all stages of the cell cycle
55. Caspase-dependent Cdk activity is a requisite effector of apoptotic death events
56. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines
57. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia